ROIV stock news · Roivant Sciences Ltd.
Get alerts for ROIV
Follow Roivant Sciences Ltd. (ROIV) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for ROIVRoivant Sciences Ltd. shares important news about brepocitinib and its Phase 3 CLARITY program.
Good for ROIVRoivant reported positive Phase 3 results for its subsidiary’s eye-disease drug program. This is encouraging for the company, though the filing gives no trial details or approval news.
Roivant Sciences held a call to discuss their earnings for the first quarter of 2027.
Good for ROIVRoivant reported progress in brepocitinib studies and received an initial Moderna settlement payment. The news supports its outlook, though FDA approval and later study results remain pending.
Roivant Sciences asks its shareholders to vote on important issues.
NeutralRoivant's 8-K reports routine shareholder votes and an exhibit; it adds no new financial information, so it does not change Roivant's outlook.
On Tuesday, 12 health care stocks saw big price changes during the day.
Good for ROIVRoivant Sciences increased 19.86% to $41.87, a sizable single-session gain that improves market sentiment.
Stocks fell today as oil prices hit $98, raising worries about inflation.
Good for ROIVRoivant jumped after its subsidiary reported success in a mid-stage trial for mosliciguat, lifting the stock sharply.
On Tuesday, Roivant Sciences, Pharvaris, IonQ, and other major stocks saw their prices go up.
Good for ROIVRoivant Sciences, IonQ, and Pharvaris reported significant clinical and financial updates, leading to notable stock price increases, while Bloom Energy was announced to join the S&P 500, contributing to its stock surge.